Steris (STE) PT Lifted at BofA/Merrill Lynch on Industry Trends; Ebola Could Buoy Shares

BofA/Merrill Lynch analyst Erin Wilson bumped his price target on Buy-rated Steris (NYSE: STE) to $58.00 (from $56.00) on encouraging hospital volume QTD .

Wilson noted the survey indicated inpatient volumes accelerated +4.0% in August (from +2.8% in July and +3.1% in June), pointing to
the second best volume quarter in over two years, likely with help from health care reform.

The analyst also notes that while the direct impact from Ebola is immaterial for STE, the threat may drive "greater awareness from health care providers and facilities on infection control protocols, which may drive demand and buoy the shares."

For an analyst ratings summary and ratings history on Steris click here. For more ratings news on Steris click here.

Shares of Steris closed at $55.26 yesterday.

You May Also Be Interested In

• Rentokil Initial (RTO) PT Lowered to $35 at Oppenheimer
• Boston Beer Company (SAM) PT Lowered to $310 at Evercore ISI
• CLSA Upgrades BNK Financial (138930:KS) to Outperform (2)